<DOC>
	<DOCNO>NCT01182493</DOCNO>
	<brief_summary>The purpose study evaluate comparative effectiveness insulin pump therapy versus multiple daily injection insulin-taking type 2 Diabetes Mellitus sub optimally control multiple daily injection ( MDI ) .</brief_summary>
	<brief_title>OpT2mise Glucose Control Type 2 Diabetes Mellitus ( DM ) With Insulin Pump Therapy</brief_title>
	<detailed_description>The type study interventional post-market release . All device investigation CE mark , use within intend use . This study design prospective randomize controlled single-arm cross-over continuation phase . Four hundred type 2 Multiple Daily Injections ( MDI ) treat patient undergo screen ( run-in ) phase 8 week . The aim screen phase eliminate study effect might result decrease HbA1c make sure patient , fail current MDI therapy , select . After screen phase , eligible patient randomise receive either Continuous Subcutaneous Insulin Infusion ( CSII ) treatment continue MDI treatment . The first 6-months phase ( 2-arms parallel ) follow another 6-months continuation phase ( single cross-over MDI arm alone switch CSII ) .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Inclusion Criteria screening : 1 . Diagnosed type 2 DM , per Investigator discretion 2 . HbA1c ( DCCTstandard ) must ≥ 8.0 % ≤12 % evidenced central lab value take screen 3 . Insulin resistance define require daily dose 0.51.8 U/Kg maximum 220 unit insulin per day 4 . Aged 30 75 year old ( inclusive ) 5 . On MDI regimen ( basal/bolus regimen longacting insulin rapid act analog ) define ≥ 3 injection per day least 3 month prior sign inform consent 6 . Ability comply technology , accord Investigator 's judgment 7 . Patients must willing undergo study procedures 8 . Female patient childbearing potential must use adequate contraception mean assess Investigator randomisation : 1 . Diagnosed type 2 DM , per Investigator discretion 2 . HbA1c ( DCCTstandard ) must ≥ 8.0 % ≤12 % evidenced central lab value 3 . Insulin resistance define require daily dose 0.71.8 U/Kg maximum 220 unit insulin per day 4 . On MDI ( basal/bolus regimen longacting insulin rapid act analog ) define ≥ 3 injection per day 5 . Ability comply technology , accord Investigator 's judgment 6 . ≥ 2.5 SMBG per day average , report Carelink clinical runin phase . 7 . Patients must willing undergo study procedures 8 . Female patient childbearing potential must use adequate contraception mean assess Investigator Exclusion Criteria : 1 . Subject history ( ≥ 2 event ) hypoglycemic seizure hypoglycemic coma within last 6 month 2 . Subject pregnant assessed pregnancy test central laboratory , plan become pregnant course study 3 . Participation another interventional clinical study , ongoing complete less 3 month prior signature Patient Informed Consent . 4 . Subject proliferative retinopathy sight threaten maculopathy 5 . Subject acute coronary syndrome ( myocardial infarction unstable angina ) within 12 month OR coronary artery revascularization bypass surgery stenting within 3 month OR transient ischemic attack ( TIA ) cerebrovascular accident ( CVA ) within 3 month OR hospitalization heart failure within 3 month current New York Functional Class III IV OR current 2nd 3rd degree heart block OR symptomatic ventricular rhythm disturbance OR thromboembolic disease within last 3 month OR 2nd degree Mobitz type II 3rd degree heart block 6 . Subject renal impairment express estimate glomerular filtration rate ( eGFR ) use Modification Diet Renal Disease ( MDRD ) formula &lt; 30 ml/min demonstrate screening central laboratory value time enrollment 7 . Subject take oral injectable steroid within last 30 day 8 . Systolic blood pressure screen visit &gt; 180 mmHg 9 . Diastolic blood pressure screen visit &gt; 110 mmHg 10 . Any disease ( eg active cancer treatment ) condition include abnormality find screen test , opinion Investigator , may preclude him/her participate study 11 . Taking medication prescribe weight loss 12 . Alcohol drug abuse , nicotine , investigator 's discretion 13 . Use GLP1 agonist pramlintide ( Symlin )</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>MDI</keyword>
	<keyword>pump therapy</keyword>
</DOC>